Skip to content

Clinical application of pathological hyperstaging (technology) of lymph nodes in the diagnosis of lymph node metastasis in cervical cancer

Clinical application of pathological hyperstaging (technology) of lymph nodes in the diagnosis of lymph node metastasis in cervical cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100050570
Enrollment
Unknown
Registered
2021-08-29
Start date
2021-12-01
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer

Interventions

Gold Standard:Lymph node gold standard test protocol
hyperstaging&#32
(technology)&#32
of&#32
lymph&#32
nodes.

Sponsors

Chengdu Women and Children's Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients who underwent radical mastectomy for FIGOIA2IIA stage cervical cancer from 2013 to 2017; 2. All lymph nodes of radical surgery specimens; 3. More than 8 lymph nodes were detected.

Exclusion criteria

Exclusion criteria: 1. Surgical specimens of carcinoma in situ; 2. Patients with cervical cancer who have not undergone radical resection; 3. The detected lymph nodes are less than or equal to 8; 4. After routine detection, the effective lymph node tissue has been removed; 5. Specimens with poor lymph node tissue handling in the past; 6. Lymph nodes were found to be adipose tissue after radical operation.

Design outcomes

Primary

MeasureTime frame
Number of lymph node metastases;SEN, SPE, ACC, AUC of ROC;

Secondary

MeasureTime frame
5-year survival rate;Pathological classification of tumor;Clinical staging;

Countries

China

Contacts

Public ContactLin Wenyi

Chengdu Women and Children's Central Hospital

3071059724@qq.com+86 18628172677

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026